Why Select Medical (SEM) is a Top Value Stock for the Long-Term

Zacks identifies Select Medical (SEM) as a top value stock, assigning it a #3 (Hold) Zacks Rank but strong 'A' ratings for both its VGM and Value Style Scores. This assessment is driven by attractive valuation metrics, including a forward P/E of 11.3, and recent upward revisions to its fiscal 2025 earnings estimates, now at $1.17 per share, alongside an average earnings surprise of +11.4%. These factors suggest SEM warrants investor consideration despite its neutral Zacks Rank, aligning with Zacks' methodology of combining strong Style Scores with a favorable Rank.

Analysis

Select Medical (SEM) is presented as a compelling case for value investors, characterized by a dichotomy between its valuation metrics and its earnings momentum rating. The company holds a top-tier 'A' grade for both its Value Style Score and its composite VGM Score, primarily driven by an attractive forward P/E ratio of 11.3. This suggests the stock is potentially undervalued relative to its future earnings potential. However, this is contrasted by its neutral Zacks Rank of #3 (Hold), which indicates a lack of significant, broad-based upward revisions in earnings estimates. Still, there are positive undercurrents, as two analysts have revised fiscal 2025 earnings estimates upward in the last 60 days, pushing the consensus EPS to $1.17. Furthermore, SEM has a strong operational track record, evidenced by an average positive earnings surprise of 11.4%, suggesting a history of exceeding market expectations.

Key Decisions for Investors

• Value-oriented investors should consider SEM for further due diligence, as its 'A' grade for value and forward P/E of 11.3 suggest it may be trading at a discount to its intrinsic value.
• The neutral #3 'Hold' rank warrants attention; investors should monitor for an acceleration in upward earnings estimate revisions, as this would be a key catalyst signaling a potential re-rating of the stock.
• Consider the company's history of delivering an average earnings surprise of +11.4% when evaluating the risk profile, as it indicates a pattern of operational outperformance that may not be fully captured in current consensus estimates.